Pearl Brings In $65M To Breathe Life Into Its Phase III Program
This article was originally published in The Pink Sheet Daily
Executive Summary
A recent financing will help Pearl Therapeutics push its lead program into late-stage trials, but further financing or a partnership will be needed before the company can file for regulatory approval.